Angiogenesis is also one of the major characteristics of ccRCC, and several targeted therapies such as sunitinib, axitinib, and other drugs inhibit ccRCC progression by targeting VEGF targets. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.